Clinical outcome and side effects of concomitant chemoradiotherapy in the treatment of locally advanced inoperable non-small cell lung cancer: our experiences
Abstract
Background/Aim. About 1.8 million new lung cancer cases are diagnosed worldwide every year, and about 1.6 million cases have a fatal outcome. Despite improvements in treatment in the previous decades, the survival of patients with lung cancer is still poor. The five-year survival rate is about 50% for patients with localized disease, 20% for patients with regionally advanced disease, 2% for patients with metastatic disease, and about 14% for all stages. The median survival of patients with untreated non-small cell lung carcinoma (NSCLC) in the advanced stage is four to five months, and the annual survival rate is only 10%. The aim of the study was to determine the results of treatment with concomitant chemoradiotherapy (CHRT) in terms of efficacy and toxicity in selected patients with advanced inoperable NSCLC. Methods. The study included data analysis of 31 patients of both sexes who were diagnosed and histopathologically verified with NSCLC in inoperable stage III and were referred by the Council for Malignant Lung Diseases to the Radiotherapy Department of the Military Medical Academy in Belgrade, Serbia for concomitant CHRT treatment. Upon expiry of the three months from the performed radiation treatment (RT), the tumor resonance was assessed based on multislice computed tomography (MSCT) examination of the chest and upper abdomen according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. According to the same criteria, progression-free survival (PFS), as well as overall survival (OS), was assessed every three months during the first two years, then every 6 months or until the onset of disease symptoms. Results. The median PFS was 13 months, and the median OS was 20 months. During and immediately after RT, 9 (29%) patients had a grade 2 or higher adverse events. Conclusion. The use of concomitant CHRT in patients in the third stage of locally advanced inoperable NSCLC provides a good opportunity for a favorable therapeutic outcome with an acceptable degree of acute and late toxicity and represents the standard therapeutic approach for selected patients in this stage of the disease.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of inci-dence and mortality worldwide for 36 cancers in 185 coun-tries. CA Cancer J Clin 2018; 68(6): 394‒424.
World Health Organization. European Mortality Database (MDB). Copenhagen, Denmark: WHO Regional Office for Europe; 2019. Available from: http://www.who.int/healthinfo/mortality_data/en/
Fossella FV, Komaki R, Putnam JB. Lung cancer. New York: Springer-Verlag; 2003.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for ad-vanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92‒8.
Kadri MA, Dussek JE. Survival and prognosis following resec-tion of primary non-small cell bronchogenic carcinoma. Eur J Cardiothorac Surg 1991; 5(3): 132‒6.
Shields TW. Surgical therapy for carcinoma of the lung. Clin Chest Med 1993; 14(1): 121‒47.
Guidelines: Lung and Chest Tumours. ESMO-MCBS Pocket Guidelines. 2018. Available from: https://www.esmo.org › guidelines
Rodrigues G, Choy H, Bradley J, Rosenzweig KE, Bogart J, Curran WJ Jr, et al. Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an Ameri-can Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 2015; 5(3): 141‒8.
NCCN Guidelines with Evidence Blocks - Non-Small Cell Lung Cancer Version 4. 2019. Available from: https://www.nccn.org › guidelines
Republican Expert Commission for the Development and Implementation of Good Clinical Practice Guidelines, Minis-try of Health of the Republic of Serbia. National guideline of good clinical practice for the diagnosis and treatment of lung cancer. Belgrade: Agency for Accreditation of Health Institu-tions; 2012. Available from: http://www.zdravlje.gov.rs/downloads/
/Decembar/Vodici/Vodic%20za%20dijagnostikovanje%20i%20lecenje%20karcinoma%20pluca.pdf
Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005; 49(1): 13‒23.
Burdett S, Stewart L, Rydzewska L. A systematic review and me-ta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thoracic Oncol-ogy 2006; 1(7): 611‒21.
Detterbeck F, Boffa D, Kim A, Tanoue L. The eighth edition lung cancer stage classification. Chest 2017; 151(1):193‒203.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Clas-sification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. J Thorac Oncol 2015; 10(9): 1243‒60.
Dobbs J, Barrett A. Practical Radiotherapy Planning: Royal Marsden Hospital Practice. 4th ed. London: Hodder Arnold; 2009.
Peter H. Radiotherapy in practice: External beam therapy. 2nd ed. Oxford: Oxford University Press; 2012.
ICRU report 62 (supplement to ICRU 50): Prescribing, re-cording and reporting photon beam therapy. Bethesda, MD, USA: International Commission on Radiation Units and Measurements; 1999.
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandre-kar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 2016; 62: 132‒7.
Nacional Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda, Maryland: National Institutes of Health; 2017.
Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103(19): 1452‒60.
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17(9): 2692‒9.
Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical re-section for stage IIIA(pN2) non-small cell lung cancer: Out-comes update of North American Intergroup 0139 (RTOG-9309). J Clin Oncol 2005; 23: 624s.
Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PA-CIFIC. J Thorac Oncol 2020; 15(2): 288‒93.
Liu L, Wang X, Ji Z, Wang J, Bi N, Hui Z, et al. Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients. Zhonghua Zhong Liu Za Zhi 2015; 37(11): 863‒7. (Chinese)
Yilmaz U, Yılmaz U, Yasar Z, Kıraklı EK, Ulger S, Ozdogan Y, et al. Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience. J Cancer Res Ther 2016; 12(1): 334‒9.
Crvenkova S. Prognostic Factors and Survival in Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy. Open Access Maced J Med Sci 2015; 3(1): 75‒9.
Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, et al. Concurrent chemoradiation therapy with oral etopo-side and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol 1996; 14(4): 1055‒64.
Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, et al. Concurrent cisplatin, etoposide, and chest radi-otherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20(16): 3454‒60.
Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34(9): 953‒62.
Gandara DR, Chanky, Albain KS, Gaspar LE, Lara PN Jr, Kelly K, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006; 8(2): 116‒21.
Wei X, Liu HH, Tucker SL, Liao Z, Hu C, Mohan R, et al. Risk factors for acute esophagitis in non-small-cell lung cancer pa-tients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66(1): 100‒7.